Quiros-Roldan E - Search Results

1

Role of systemic inflammation scores for prediction of clinical outcomes in patients treated with atazanavir not boosted by ritonavir in the Italian MASTER cohort.

Postorino MC, Prosperi M, Focà E, Quiros-Roldan E, Di Filippo E, Maggiolo F, Borghetti A, Ladisa N, Di Pietro M, Gori A, Sighinolfi L, Pan A, Mazzini N, Torti C. Postorino MC, et al. BMC Infect Dis. 2017 Mar 15;17(1):212. doi: 10.1186/s12879-017-2322-z. BMC Infect Dis. 2017. PMID: 28298195 Free PMC article.

2

Detection of clonal T cell populations with closely related T cell receptor junctional sequences in persons at high risk for human immunodeficiency virus (HIV) infection and in patients acutely infected with HIV.

Bettinardi A, Imberti L, Sottini A, Quiròs-Roldan E, Puoti M, Castelli F, Cadeo GP, Gorla R, Primi D. Bettinardi A, et al. J Infect Dis. 1997 Feb;175(2):272-82. doi: 10.1093/infdis/175.2.272. J Infect Dis. 1997. PMID: 9203647

3

HIV-1 pharmacoresistance: clinical and therapeutic implications.

Carosi G, Torti C, Palvarini L, Quiros Roldan E. Carosi G, et al. J Biol Regul Homeost Agents. 1999 Jul-Sep;13(3):163-71. J Biol Regul Homeost Agents. 1999. PMID: 10560750 Review.

4

Liver damage and kinetics of hepatitis C virus and human immunodeficiency virus replication during the early phases of combination antiretroviral treatment.

Puoti M, Gargiulo F, Quiros Roldan E, Chiodera A, Palvarini L, Spinetti A, Zaltron S, Putzolu V, Zanini B, Favilli F, Turano A, Carosi G. Puoti M, et al. J Infect Dis. 2000 Jun;181(6):2033-6. doi: 10.1086/315529. Epub 2000 May 31. J Infect Dis. 2000. PMID: 10837187

5

Analysis of HIV-1 mutation patterns in patients failing antiretroviral therapy.

Quiros-Roldan E, Signorini S, Castelli F, Torti C, Patroni A, Airoldi M, Carosi G. Quiros-Roldan E, et al. J Clin Lab Anal. 2001;15(1):43-6. doi: 10.1002/1098-2825(2001)15:1<43::aid-jcla9>3.0.co;2-i. J Clin Lab Anal. 2001. PMID: 11170234 Free PMC article.

6

HIV-1 multi-dideoxynucleoside resistance mutation (Q151M): prevalence, associated resistance mutations and response to antiretroviral salvage treatment.

Quiros-Roldan E, Bertelli D, Signorini S, Airoldi M, Torti C, Moretti F, Carosi G. Quiros-Roldan E, et al. Microbios. 2001;106(414):137-45. Microbios. 2001. PMID: 11506064

7

[New strategies and new drugs in the salvage therapy for HIV infection].

Quirós-Roldán E, Torti C, Pan A, Carosi G. Quirós-Roldán E, et al. Med Clin (Barc). 2002 Feb 23;118(6):222-4. doi: 10.1016/s0025-7753(02)72341-5. Med Clin (Barc). 2002. PMID: 11864546 Review. Spanish. No abstract available.

8

Genotype resistance profiles in patients failing an NNRTI-containing regimen, and modifications after stopping NNRTI therapy.

Quiros-Roldan E, Airoldi M, Moretti F, Fausti C, Pan A, Casari S, Torti C, Castelli F, Carosi G. Quiros-Roldan E, et al. J Clin Lab Anal. 2002;16(2):76-8. doi: 10.1002/jcla.10022. J Clin Lab Anal. 2002. PMID: 11948795 Free PMC article.

9

No evidence of benefical effect of GB virus type C infection on the course of HIV infection.

Quiros-Roldan E, Maroto MC, Torti C, Moretti F, Casari S, Pan A, Carosi G. Quiros-Roldan E, et al. AIDS. 2002 Jul 5;16(10):1430-1. doi: 10.1097/00002030-200207050-00019. AIDS. 2002. PMID: 12131224 No abstract available.

10

Effect of highly active antiretroviral therapy (HAART) and hepatitis C Co-infection on hyperlipidemia in HIV-infected patients: a retrospective longitudinal study.

Patroni A, Torti C, Tomasoni L, Quiros Roldan E, Bertelli D, Puoti M, Cadeo GP, Sleiman I, Tinelli C, Carosi G, Castelli F. Patroni A, et al. HIV Clin Trials. 2002 Nov-Dec;3(6):451-61. doi: 10.1310/w024-qc4t-nxu0-tkyt. HIV Clin Trials. 2002. PMID: 12501128

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

307 results

Search Page

Filters